Safety and Weight Loss Efficacy Confirmed in Phase 1 Clinical Trial
Yunovia, the new drug research and development company of Ildong Pharmaceutical Group, announced on June 10 that it will participate in the American Diabetes Association (ADA) conference, which will be held in Chicago, United States, from June 20 to 23, and will present research results related to its metabolic disease drug candidate 'ID110521156,' targeting obesity and diabetes.
According to Yunovia, ID110521156 is a GLP-1 RA (glucagon-like peptide-1 receptor agonist) class drug. It performs the same functions as the GLP-1 hormone, which is involved in insulin synthesis and secretion, reduction of blood glucose levels, regulation of gastrointestinal motility, and appetite suppression in the body.
In particular, the company explained that ID110521156 is a synthetic oral (tablet) drug candidate based on a small molecule compound, which offers clear advantages such as superior productivity and excellent convenience of use compared to existing peptide-based injectable therapies.
Yunovia is conducting clinical studies to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of ID110521156. Last year, the company completed a Phase 1 single ascending dose (SAD) trial and is currently conducting a multiple ascending dose (MAD) follow-up study.
At this conference, Yunovia plans to present notable findings in a poster format, based on interim results and related data from the Phase 1 SAD and MAD studies of ID110521156.
According to the company, in the Phase 1 SAD trial, ID110521156 showed relatively fewer gastrointestinal side effects across the effective dose range compared to other drugs in the GLP-1 RA class.
Based on these results, the MAD study is being conducted by applying the effective dose immediately, without a titration process that gradually increases the dose from a low level while monitoring for side effects. Interim results have confirmed dose-dependent weight loss efficacy.
An Ildong Pharmaceutical Group representative stated, "To meet the trends and needs of the global market, we have been collaborating with major international pharmaceutical companies from the clinical study design stage," and added, "Along with clinical development, we will actively pursue out-licensing and the search for partnership opportunities."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
